ALKS
Alkermes plc
Set alert
- YTD
- +62.04%
- 1 year
- +47.11%
- Open
- 46.05
- Prev close
- 45.37
- Mkt cap
- 7.61B
- Vol
- 1.11M
- Avg vol
- 1.84M
- EPS
- 0.38
- P/E
- 119.32
- Div yield
- 0.00%
More statistics
- Low
- 44.78
- High
- 46.35
- Forward P/E
- 25.04
- Beta
- 0.27
- Short ratio
- 7.67
- Inst. own
- 107.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 3, 2026
- 50-d avg
- 44.11
- 200-d avg
- 40.40
- 1y target
- 56.21
News
1 day ago businesswire.com
Alkermes Expands ALKS 7290 Development Program With Initiation of Phase 2 Study for the Adjunctive Treatment of Major Depressive Disorder (MDD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the initiation of a phase 2 study evaluating the safety and efficacy of ALKS 7290 as an adjunctive therapy to antidepressants in…
2 days ago seekingalpha.com
Alkermes Q3 Preview: The Pipeline Looks Strong, But Earnings Tell Another Story
Alkermes is maintained at a 'Buy' with a $57 price target, driven by LUMRYZ's commercial momentum and a promising neuroscience pipeline. 3Q26 revenue is projected to rise 18% year-over-year but…
5 days ago defenseworld.net
Alkermes plc $ALKS Position Cut by Robeco Institutional Asset Management B.V.
Robeco Institutional Asset Management B.V. trimmed its position in Alkermes plc (NASDAQ: ALKS) by 37.6% in the third quarter, according to the company in its most recent Form 13F filing with the…
1 week ago gurufocus.com
Alkermes to Report Third Quarter Financial Results on November 3, 2026
[url="]Alkermes plc[/url] (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to di
1 week ago businesswire.com
Alkermes to Report Third Quarter Financial Results on November 3, 2026
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Tuesday, November 3, 2026 to discuss the company's third…
1 week ago zacks.com
Earnings Preview: Alkermes (ALKS) Q3 Earnings Expected to Decline
Alkermes (ALKS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
1 week ago defenseworld.net
Alkermes plc $ALKS Shares Sold by State of Alaska Department of Revenue
State of Alaska Department of Revenue lessened its holdings in shares of Alkermes plc (NASDAQ: ALKS) by 43.6% during the undefined quarter, according to its most recent 13F filing with the SEC. The…
-
2 weeks ago benzinga.com
Alkermes Plans To Present Two Oral Presentations And Six Posters From Portfolio Of Sleep Medicine Research At ESRS 28th Congress, Sleep Europe 2026
— Data From Vibrance-1 Phase 2 Study Lancet Neurology Publication Evaluating Alixorexton in Narcolepsy Type 1 and Additional Data From Long-Term Extension Study in Narcolepsy Type 1 and Type 2 to be…
2 weeks ago businesswire.com
Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at Sleep Europe 2026, Underscoring Leadership in Sleep Medicine Research
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced plans to present two oral presentations and six posters from its industry-leading portfolio of sleep medicine research at the…
3 weeks ago zacks.com
4 CNS Drug Stocks Worth Watching This World Mental Health Day
AXSM, NBIX, ALKS and ACAD are advancing CNS treatments for mental health disorders, with growing product sales, pipeline progress and new growth opportunities.
3 weeks ago seekingalpha.com
Stock Picks From Seeking Alpha's September 2026 New Analysts
Seeking Alpha welcomed 38 new analysts in September 2026. This article showcases their top picks and investment strategies. Highlighted companies include Qualcomm, Teladoc, and NewLake Capital…
3 weeks ago defenseworld.net
Critical Survey: Alkermes (NASDAQ:ALKS) and uniQure (NASDAQ:QURE)
Alkermes (NASDAQ: ALKS - Get Free Report) and uniQure (NASDAQ: QURE - Get Free Report) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the…
1 month ago zacks.com
LQDA versus ALKS: Which Biotech Stock Is the Better Buy Now?
LQDA's Yutrepia drives rapid growth, while ALKS benefits from a diversified portfolio, Lumryz and a broader pipeline.
1 month ago seekingalpha.com
Alkermes: Idiopathic Hypersomnia Could Expand Lumryz Into A Larger Growth And Margin Driver
Alkermes is positioned for significant growth through LUMRYZ's potential expansion into idiopathic hypersomnia (IH), following positive Phase 3 results. LUMRYZ's IH indication could drive incremental…
-
1 month ago benzinga.com
Goldman Sachs Reinstates Neutral on Alkermes, Announces $50 Price Target
Goldman Sachs analyst Andrea Newkirk reinstates Alkermes (NASDAQ:ALKS) with a Neutral and announces $50 price target.
1 month ago zacks.com
Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290
ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.
-
1 month ago benzinga.com
RBC Capital Reiterates Outperform on Alkermes, Maintains $56 Price Target
RBC Capital analyst Leonid Timashev reiterates Alkermes (NASDAQ:ALKS) with a Outperform and maintains $56 price target.
1 month ago benzinga.com
Meta To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts upgraded Fifth Third to Buy and adjusted price targets for Exelon, Alaska Air, Fair Isaac, Meta, Alkermes, Twilio and Warner Bros. Discovery.
-
1 month ago benzinga.com
Baird Maintains Outperform on Alkermes, Raises Price Target to $61
Baird analyst Joel Beatty maintains Alkermes (NASDAQ:ALKS) with a Outperform and raises the price target from $58 to $61.
1 month ago benzinga.com
Alkermes Says Experimental Drug Could Open New Path in ADHD Treatment
Alkermes reports positive Phase 1b data for ALKS 7290, showing clinical proof-of-concept for ADHD treatment. Learn key findings.
1 month ago investors.com
How Alkermes Used Its Narcolepsy Playbook In ADHD — And Seemingly Won
Alkermes stock jumped Monday on the first proof-of-concept for its orexin-modulating drug in adults with ADHD.
-
1 month ago benzinga.com
Alkermes Shares Topline Results From Phase 1 Proof-of-concept Study Evaluating ALKS 7290 For Attention-deficit Hyperactivity Disorder, Showing Meaningful Improvements In Patients
Alkermes plc (NASDAQ:ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company’s novel, investigational orexin 2 receptor (OX2R) agonist…
1 month ago businesswire.com
Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced positive topline results from a phase 1 proof-of-concept study evaluating ALKS 7290, the company's novel, investigational orexin 2…
1 month ago businesswire.com
Alkermes Announces Appointment of Anne C. Whitaker to Board of Directors
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced the appointment of a new independent director, Anne C. Whitaker, to the company's Board of Directors (the Board). Ms. Whitaker is…
1 month ago defenseworld.net
California State Teachers Retirement System Increases Holdings in Alkermes plc $ALKS
California State Teachers Retirement System increased its stake in Alkermes plc (NASDAQ: ALKS) by 5,527.7% in the second quarter, according to the company in its most recent disclosure with the SEC.…
1 month ago seekingalpha.com
Alkermes: A Slow-Burning Buy Prospect On Orexin-Agonist Promise
Alkermes plc is upgraded from Hold to Buy, driven by robust revenue growth, pipeline momentum, and strategic positioning in sleep and CNS disorders. Acquisition of Avadel and Lumryz launch propel…
1 month ago businesswire.com
Alkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on Friday, Sept. 11, 2026. Now…
2 months ago benzinga.com
10 Health Care Stocks Whale Activity In Today’s Session
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
4 months ago benzinga.com
Micron To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top analysts changed outlook on top names: Intuit downgraded, Alkermes price target raised, Carmax target increased, Sezzle target up, Biogen target raised, Progressive target cut.
-
4 months ago benzinga.com
Venu Holding Pursues $80M Sale-Leaseback Transaction On Parking Garage Asset At Sunset Amphitheater In McKinney, Texas
Company seeks to advance national expansion through innovative financing model; Founder personally invested in Company's first sale-leaseback transaction as part of an approximately $250 million…
7 months ago benzinga.com
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday
US stocks rise, Dow Jones gains 600+ pts. Apellis Pharma shares surge 136.4% after buyout by Biogen for $41/share. Other gainers incl. Centessa, Annexon, Agios, Fulcrum, Scholar Rock, Alkermes, Wave…
-
8 months ago benzinga.com
Earnings Scheduled For February 25, 2026
Earnings Scheduled For February 25, 2026
8 months ago benzinga.com
Southern To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Friday
Southern To Rally More Than 9%? Here Are 10 Top Analyst Forecasts For Friday
9 months ago benzinga.com
Jim Cramer Says Sell Super Micro — Calls A European Chipmaker 'Cheap And Good'
Jim Cramer recommended selling Super Micro Computer Inc. and doesn't recommend Alkermes plc. Huntington Bancshares is 'terrific.' Smith & Nephew plc should be sold. Cramer also recommends buying…
11 months ago benzinga.com
10 Health Care Stocks With Whale Alerts In Today's Session
10 Health Care Stocks With Whale Alerts In Today's Session
11 months ago benzinga.com
12 Health Care Stocks Moving In Thursday's After-Market Session
12 Health Care Stocks Moving In Thursday's After-Market Session
11 months ago benzinga.com
This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
This Alkermes Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Tuesday
1 year ago benzinga.com
Earnings Scheduled For October 28, 2025
Earnings Scheduled For October 28, 2025
1 year ago benzinga.com
Deal Dispatch: From Four Roses Bourbon To Quantum Stakes, Here Are This Week's Sector Shake Ups
Four Roses, Six Flags, and Trump's potential Quantum investments: This week's deal activity involves big bets across various sectors.
1 year ago benzinga.com
This Ciena Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
1 year ago benzinga.com
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
Macy's Increases FY2025 Outlook, Joins REV Group, HealthEquity, Alphabet and Wellness And Other Big Stocks Moving Higher On Wednesday
1 year ago benzinga.com
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
This Unisys Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
1 year ago benzinga.com
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Bruker, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
1 year ago benzinga.com
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday
-
1 year ago benzinga.com
Earnings Scheduled For February 12, 2025
Earnings Scheduled For February 12, 2025
-
1 year ago benzinga.com
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
-
2 years ago benzinga.com
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Why General Dynamics Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session